Fresh analysis reveals that patients who discontinue blockbuster slimming jabs like semaglutide or tirzepatide may regain shed pounds much more quickly than those who end traditional lifestyle plans.
Published data in a leading medical journal demonstrates that while obese individuals often shed about a fifth of their total mass while on the medication, the weight is regained at an average rate of 0.8 kg per month once they quit.
"Users purchasing these drugs should be informed of the risk of fast weight regain when the medication ends," stated expert Dr. Susan Jebb.
That rate of recovery means a return to starting weight in about a year and a half.
Weighing Therapies
The analysis, which looked at 37 of studies involving over 9,000 of patients, contrasted the effects of GLP-1 agonists with other pills.
Scientists point out that people who lose weight through lifestyle changes alone usually experience a more gradual creep back—approximately 0.1 kg a month—once they finish.
The Reason for the Quick Rebound
Experts propose the mode of action of the injections accounts for the heightened rebound.
The injections copy a body's own chemical called GLP-1, which controls appetite.
"Long-term administration of GLP-1 concentrations several times higher than normal might result in the body to produce less of its endogenous GLP-1, and could lessen responsiveness to its actions," explained Dr. Adam Collins, a dietetics researcher.
"Withdrawal of this GLP-1 'fix' results in hunger is unsuppressed, making overeating a significant risk."
A Lifelong Condition?
Medical guidelines suggest the jabs for people with weight-linked medical conditions, alongside recommended diet and exercise modifications.
Professionals say that, given the significant potential of weight regain, the therapy is often long-term.
This perspective is echoed by pharmaceutical companies, who note that the findings "underscore the long-term nature of obesity," similar to managing conditions like diabetes.
Patient Accounts
People who have discontinued the medication report a powerful resurgence of appetite.
"It felt as if a switch flipping and I was suddenly extremely hungry," recalled an individual.
This challenge is compounded if individuals have not adopted sustainable lifestyle or habit modifications during treatment.
Widespread Adoption
Figures show that millions of people in the UK have used weight-loss jabs in the last 12 months, with demand continuing to grow.
- Adoption is more common among women than males.
- The middle-aged demographic shows the greatest level of interest.
- Many access the medications through private prescriptions rather than public health services.
Finally, experts caution that while the jabs are effective agents for shedding pounds, they are not a permanent solution and maintained weight loss likely depends on ongoing lifestyle changes.
